Sun Oct 20 06:17:50 UTC 2024: Here are the important points from the news article:

1. **Amneal Pharmaceuticals Investment**: Amneal Pharmaceuticals is set to invest $200 million in India, signaling expansion plans in the region.

2. **Torrent Pharma Penalty**: Torrent Pharma has been fined Rs 6.32 lakh by the National Pharmaceutical Pricing Authority (NPPA) for price violations.

3. **Alembic Pharma Approval**: Alembic Pharma received approval from the USFDA for a generic drug to treat schizophrenia.

4. **Entod Pharma Development**: Entod Pharma has been granted approval by the DCGI for presbyopia eye drops.

5. **Mankind Pharma Fundraising**: Mankind Pharma has approved a fundraising initiative worth Rs 10,000 crore.

6. **Sun Pharma Licensing Deal**: Sun Pharma has licensed a cancer drug, Fibromun, from Philogen for further development.

7. **Piramal Pharma Goals**: Piramal Pharma has set a target to reach USD 2 billion in revenue by FY30.

8. **India-Uzbekistan Collaboration**: India and Uzbekistan are enhancing cooperation on pharmaceutical safety and quality standards.

9. **Senores Pharma IPO**: Senores Pharma plans to raise Rs 500 crore through an IPO, aiming for expansion in the US market.

10. **Market Volatility and Fund Inflows**: Indian markets are anticipated to be volatile due to upcoming Q2 corporate earnings, while mid- and small-cap mutual funds experienced significant inflows of Rs 30,350 crore in H1 FY25.

11. **Government Initiative**: The Indian government has included the Prime Minister’s Internship Scheme as a common theme for Corporate Public Sector Enterprises’ (CPSEs) Corporate Social Responsibility (CSR) initiatives.

Read More